Original Source(s)
Related Content
FDA approves serial liquid biopsy testing
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026
-
2 min
Roswell Park Launches Exclusive Phase 1 Clinical Trial of ‘Armored’ CAR T-Cell Therapy for Ovarian Cancer
Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.
June 24, 2026
-
3 min
Endometrial cancer drug cuts progression or death risk 41%
FDA grants Priority Review following improved survival versus chemotherapy in phase 3 trial.
by Mouj Hijazi
October 27, 2026
-
3 min